NMS Oncology is strategically committed to partnerships to promote discovery and development of innovative cancer treatments.

Thus, we are open to establish R&D collaborative undertakings by applying our Capabilities and Technology Platforms to new drug development in the field of oncology.

We have entered in to collaborative deals with the following companies and institutions:

Nerviano Medical Sciences announces new License Agreement

Nerviano Medical Sciences announces a new License Agreement with Genentech for small molecule inhibitors

A new agreement has stated the official separation between Nerviano Medical Sciences and Pfizer

Nerviano Medical Sciences announces a new Collaboration Agreement with Genentech to discover Antibody Drug Conjugates

Nerviano Medical Sciences and Genentech joint strenghts

Nerviano Medical Sciences expands partnership with ChemDiv in lead discovery

Brostallicin, the new oncology drug candidate, discovered by NMS was licensed to CTI

Agreement with BRISTOL-MYERS SQUIBB